Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

L Kazianka; T Pemovska; J Rohrbeck; C Kornauth; A Pichler; C Agreiter; S Lubowitzki; K Prochazka; P Neumeister; C Schmitt; R Greil; W Willenbacher; D Wolf; U Jaeger; I Simonitsch-Klupp; PB Staber

doi:10.1182/blood-2023-189856

Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

L Kazianka, T Pemovska, J Rohrbeck, C Kornauth, A Pichler, C Agreiter, S Lubowitzki, K Prochazka, P Neumeister, C Schmitt, R Greil, W Willenbacher, D Wolf, U Jaeger, I Simonitsch-Klupp, PB Staber

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Journal	BLOOD
Volume	142
DOIs	https://doi.org/10.1182/blood-2023-189856
Publication status	Published - 2023

Access to Document

10.1182/blood-2023-189856

Cite this

Kazianka, L., Pemovska, T., Rohrbeck, J., Kornauth, C., Pichler, A., Agreiter, C., Lubowitzki, S., Prochazka, K., Neumeister, P., Schmitt, C., Greil, R., Willenbacher, W., Wolf, D., Jaeger, U., Simonitsch-Klupp, I., & Staber, PB. (2023). Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial. BLOOD , 142. https://doi.org/10.1182/blood-2023-189856

Kazianka, L ; Pemovska, T ; Rohrbeck, J et al. / Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial. In: BLOOD 2023 ; Vol. 142.

@article{3a1868b3e5014718bbbc1468383e06f7,

title = "Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial",

author = "L Kazianka and T Pemovska and J Rohrbeck and C Kornauth and A Pichler and C Agreiter and S Lubowitzki and K Prochazka and P Neumeister and C Schmitt and R Greil and W Willenbacher and D Wolf and U Jaeger and I Simonitsch-Klupp and PB Staber",

year = "2023",

doi = "10.1182/blood-2023-189856",

language = "English",

volume = "142",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

}

Kazianka, L, Pemovska, T, Rohrbeck, J, Kornauth, C, Pichler, A, Agreiter, C, Lubowitzki, S, Prochazka, K, Neumeister, P, Schmitt, C, Greil, R, Willenbacher, W, Wolf, D, Jaeger, U, Simonitsch-Klupp, I & Staber, PB 2023, 'Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial', BLOOD , vol. 142. https://doi.org/10.1182/blood-2023-189856

Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial. / Kazianka, L; Pemovska, T; Rohrbeck, J et al.
In: BLOOD , Vol. 142, 2023.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

AU - Kazianka, L

AU - Pemovska, T

AU - Rohrbeck, J

AU - Kornauth, C

AU - Pichler, A

AU - Agreiter, C

AU - Lubowitzki, S

AU - Prochazka, K

AU - Neumeister, P

AU - Schmitt, C

AU - Greil, R

AU - Willenbacher, W

AU - Wolf, D

AU - Jaeger, U

AU - Simonitsch-Klupp, I

AU - Staber, PB

PY - 2023

Y1 - 2023

U2 - 10.1182/blood-2023-189856

DO - 10.1182/blood-2023-189856

M3 - Abstract (Journal)

SN - 0006-4971

VL - 142

JO - BLOOD

JF - BLOOD

ER -

Kazianka L, Pemovska T, Rohrbeck J, Kornauth C, Pichler A, Agreiter C et al. Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial. BLOOD . 2023;142. doi: 10.1182/blood-2023-189856